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Gut bacteria produce numerous metabolites that can circulate systemically andinﬂuence host physiology (1). Indole-3-propionic acid (IPA) is the ﬁrst microbiome-
derived metabolite with the potential to impact tuberculosis, now the single leading
infectious cause of death in adults, surpassing HIV (2). IPA is found in human serum,
has been shown to inhibit -amyloid ﬁbril formation, and can act as a neuropro-
tectant against a variety of oxidotoxins (3). It is in early clinical development to treat
patients with Friedreich’s ataxia (ClinicalTrials.gov identiﬁer NCT01898884). In the
human host, IPA is produced by Clostridium sporogenes and other gut symbionts
from the aromatic amino acid tryptophan, revealing a clear association between
circulating IPA and the presence of the producing species in mouse gut (4).
Importantly, IPA was shown to impact the intestinal barrier and systemic host
immunity in mice (4). The recent ﬁndings of Negatu et al., linking IPA and tuber-
culosis (5), thus constitute exciting new developments in the role of the micro-
biome in infectious diseases.
In a whole-cell screen of a fragment library designed to identify novel antitubercu-
losis compounds, Negatu et al. discovered that IPA exerts antitubercular activity in vitro.
Efﬁcacy studies in M. tuberculosis-infected mice showed that the compound is also
active in vivo (5). This suggests for the ﬁrst time a functional link between gut
microbiota and tuberculosis. Whether the effect of IPA is due to direct antibacterial
activity, indirect immunomodulatory functions, or a combination of both remains to be
determined.
While there is increasing interest in associations between gut microbiome species
and disease state, the ﬁnding that a metabolite produced by the gut microbiota shows
antituberculosis activity in vitro and in vivo is the ﬁrst tangible indication for an impact
of the microbiome on tuberculosis. This discovery opens up a whole series of
questions. Is there a role for IPA in tuberculosis susceptibility or progression to and
severity of disease? Does the metabolite support latent tuberculosis infection?
Could IPA be useful as an add-on to current antituberculosis drug regimens to
accelerate cure? Which bacterial and host factors are involved in the mechanism of
action of IPA? Can medicinal chemists design a new antituberculous agent using
IPA as a lead compound?
Negatu’s results highlight the promise of IPA as a potential “low-hanging fruit” to
treat tuberculosis, since it is in clinical development for another disease indication and
has thus met stringent tolerability criteria in preclinical studies. Not only could IPA be
investigated as an add-on to current antituberculous drug regimens, it also consti-
tutes—owing to its small size and attractive physicochemical properties—an ideal
starting point for target-based drug optimization.
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